Ironwood Pharmaceuticals Files 8-K on Shareholder Votes
Ticker: IRWD · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, regulatory-filing
TL;DR
Ironwood Pharma filed an 8-K for shareholder votes - nothing else to see here.
AI Summary
Ironwood Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official record of the company's compliance with reporting requirements regarding shareholder decisions.
Why It Matters
This filing indicates that Ironwood Pharmaceuticals held a shareholder vote, which is a standard corporate governance procedure. The outcome of such votes can impact the company's strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — This is a routine filing for a shareholder vote and does not appear to contain any new material information or significant corporate events.
Key Players & Entities
- IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
- June 21, 2024 (date) — Date of Report
- 001-34620 (other) — Commission File Number
- 04-3404176 (other) — I.R.S. Employer Identification Number
- 100 Summer Street, Suite 2300 (address) — Principal executive offices
- Boston, Massachusetts (location) — Principal executive offices location
- 02110 (zip_code) — Principal executive offices zip code
- 617-621-7722 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Ironwood Pharmaceuticals' security holders?
The filing states that it is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 regarding 'Submission of Matters to a Vote of Security Holders,' but does not detail the specific proposals voted upon.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 21, 2024, which is also the date of the report.
What is Ironwood Pharmaceuticals' principal executive office address?
The principal executive offices are located at 100 Summer Street, Suite 2300, Boston, Massachusetts 02110.
What is Ironwood Pharmaceuticals' telephone number?
The registrant's telephone number, including area code, is (617) 621-7722.
Under which state was Ironwood Pharmaceuticals incorporated?
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-21 07:30:16
Key Financial Figures
- $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
Filing Documents
- tm2417654d2_8k.htm (8-K) — 37KB
- 0001104659-24-073736.txt ( ) — 207KB
- irwd-20240621.xsd (EX-101.SCH) — 3KB
- irwd-20240621_lab.xml (EX-101.LAB) — 33KB
- irwd-20240621_pre.xml (EX-101.PRE) — 22KB
- tm2417654d2_8k_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, Ironwood Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The final voting results for the Annual Meeting are as follows: 1. The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes: Director Nominee For Withheld Broker Non-Votes Mark Currie, Ph.D. 130,019,704 5,472,128 7,708,364 Alexander Denner, Ph.D. 125,450,072 10,041,760 7,708,364 Andrew Dreyfus 129,704,783 5,787,049 7,708,364 Jon Duane 127,436,834 8,054,998 7,708,364 Marla Kessler 130,081,722 5,410,110 7,708,364 Thomas McCourt 133,639,699 1,852,133 7,708,364 Julie McHugh 124,822,215 10,669,617 7,708,364 Catherine Moukheibir 129,803,799 5,688,033 7,708,364 Jay Shepard 133,672,033 1,819,799 7,708,364 2. The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting, based on the following votes: For Against Abstain Broker Non-Votes 127,439,687 7,953,508 98,637 7,708,364 3. The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024, based on the following votes: For Against Abstain Broker Non-Votes 136,781,986 6,305,538 112,672 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: June 21, 2024 By: /s/ Sravan K. Emany Name: Sravan K. Emany Title: Senior Vice President, Chief Financial Officer